Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D47.02Systemic mastocytosis

✓ Billable / specificCC — complication/comorbidity

D47.02 is a valid, billable ICD-10-CM code for systemic mastocytosis. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2018 (effective October 1, 2017). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About D47.02

D47.02 is the ICD-10-CM diagnosis code for systemic mastocytosis. It belongs to category D47 (other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue), block D37-D48 (neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D47.0 (mast cell neoplasms of uncertain behavior), D47.02 is specifically for systemic mastocytosis. Related codes cover cutaneous mastocytosis (D47.01) and other mast cell neoplasms of uncertain behavior (D47.09).

Don't report D47.02 together with the conditions in its Excludes1 note: aggressive systemic mastocytosis (C96.21) and mast cell leukemia (C94.3-).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC, relative weight 6.2481), DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC, relative weight 2.2023), DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC, relative weight 1.1272), DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC, relative weight 4.6059), DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, relative weight 2.2515), DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, relative weight 1.2995) and 3 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2018, effective October 1, 2017.

Before ICD-10, this condition was coded in ICD-9-CM as 238.5 (neoplasm of uncertain behavior of histiocytic and mast cells).

Coding notes

Applicable toConditions and synonyms classified to this code
  • Indolent systemic mastocytosis
  • Isolated bone marrow mastocytosis
  • Smoldering systemic mastocytosis
  • Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
Excludes1Not coded here — never report together with this code
  • aggressive systemic mastocytosis (C96.21)
  • mast cell leukemia (C94.3-)
Code alsoTwo codes may be needed; sequencing depends on circumstances
  • , if applicable, any associated hematological non-mast cell lineage disease, such as:
  • acute myeloid leukemia (C92.6-, C92.A-)
  • chronic myelomonocytic leukemia (C93.1-)
  • essential thrombocytosis (D47.3)
  • hypereosinophilic syndrome (D72.1)
  • myelodysplastic syndrome (D46.9)
  • myeloproliferative syndrome (D47.1)
  • non-Hodgkin lymphoma (C82-C85)
  • plasma cell myeloma (C90.0-)
  • polycythemia vera (D45)

Notes that apply from higher levels

Instructions written at a parent level also apply to D47.02.

› From D47.0 Mast cell neoplasms of uncertain behavior
Excludes1
  • congenital cutaneous mastocytosis (Q82.2)
  • histiocytic neoplasms of uncertain behavior (D47.Z9)
  • malignant mast cell neoplasm (C96.2-)

Broader instructions also apply from D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes and Chapter 2: Neoplasms.

Alphabetic index entries

5 entries

Terms in the official ICD-10-CM index that lead to D47.02.

Codes whose notes reference D47.02

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

ICD-9-CM equivalent

Converter →
  • 238.5Neoplasm of uncertain behavior of histiocytic and mast cellsapproximate

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2018 (effective 10/1/2017): Added
  • No changes since FY2018.

Common questions about D47.02

Is D47.02 billable?

Yes. D47.02 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D47.02 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict D47.02 as a principal diagnosis.

Is D47.02 a CC or MCC?

D47.02 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.

What DRG does D47.02 group to?

D47.02 is used in the MS-DRG v44.0 logic for MS-DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC), MS-DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC), MS-DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC), MS-DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC), MS-DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC), MS-DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC) and 3 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

What is the ICD-9 code for D47.02?

The CMS General Equivalence Mappings map D47.02 to ICD-9-CM 238.5.